SWAT

PERFECT CIRCLE WEBSITE

http://www.pcpaintball.com/index.html

http://www.pcpaintball.com/product.html

http://www.pcpaintball.com/applications....

http://www.pcpaintball.com/manufacturing...

three day settlement is today..... from Monday's run

BUY BUY BUY to double digits

Medarex Acquires ANTI-PSMA Antibody Rights From Northwest Biotherapeutics

Medarex Also Enters Into Cross-License Agreement
With Millennium for Anti-PSMA Antibody Patents

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ --
Medarex, Inc. (Nasdaq: MEDX) today announced it has acquired from
Northwest Biotherapeutics, Inc. (Nasdaq: NWBT) full therapeutic development
and commercialization rights to MDX-070, a fully human antibody to PSMA
(prostate specific membrane antigen), together with an assignment of certain
patents relating to anti-PSMA antibodies and rights to two additional
cancer-related disease targets. In addition, Medarex will receive common stock
and warrants to acquire common stock from Northwest Biotherapeutics (NWBio).
In return, NWBio will receive certain up-front payments as well as certain
additional intellectual property rights. NWBio may also receive royalties on
products developed by Medarex based on these disease targets. In a prior
agreement, Medarex and NWBio had agreed to share the therapeutic development
and commercialization rights and obligations with respect to MDX-070 and the
additional targets.

Medarex has also entered into a royalty-free, worldwide, non-exclusive
cross-license agreement with Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM)
for certain patents relating to antibodies against PSMA.

"We are enthusiastic about the potential for MDX-070, and we look forward
to initiating clinical trials with the product," said Donald L. Drakeman,
Ph.D., President and Chief Executive Officer of Medarex.

About MDX-070

MDX-070 is a fully human antibody that targets prostate specific membrane
antigen, or PSMA, a cell surface marker that is preferentially expressed on
malignant prostate tissues. Preclinical studies using human prostatic cancer
cells suggest that MDX-070 may effectively target prostate tumor cells in
patients.

According to the American Cancer Society, other than skin cancer, prostate
cancer is the most common type of cancer found in American men and is the
second leading cause of cancer deaths in men, exceeded only by lung cancer.
The American Cancer Society estimates that in 2002 there will be about 189,000
new cases of prostate cancer in the United States, and about 30,200 men will
die of the disease.

MEDX and NWBO has cancer partnership

http://www.nwbio.com/downloads/Northwest%20Biotherapeutics%20Gets%20Key%20Patent%20for%20Cancer%20Th...

this MEDX partnership is awsome

MEDX partnership

http://www.nwbio.com/downloads/Northwest%20Biotherapeutics%20Gets%20Key%20Patent%20for%20Cancer%20Th...

NWBO SHOULD BE $10 BY NOW

WAIT TILL IT ANNOUNCES ITS PHASE III TRIAL IN PROSTATE NOW IT HAS MONEY

WATCH OUT DNDN

ITS ALIVEEEEEEEEEEEEE

NWBO SWAT HOKU XWG VICL CNLG

MY BEST STOCK PLAYS F 2007

it seems that NWBO has not started its Phase III trial of its prostate cancer vaccine due to lack of cash... but that might change since it got cash NOW

Genesis Worldwide Inc.'s Light-Steel Framing Technology Introduced to Dubai's Booming Construction Industry



Last Update: 9:00 AM ET Jul 12, 2007


MISSISSAUGA, ON, July 12, 2007 /PRNewswire-FirstCall via COMTEX/ -- Genesis Worldwide Inc. ("Genesis"), TSX/AIM: GWI, a leading provider of green structural building technology using light-steel, announces the signing of a technology license and service agreement with Manazil Steel Framing Factory ("Manazil"), a newly formed subsidiary of Khalifa Al Fahad Company of Abu Dhabi, United Arab Emirates, an Emirates building construction company established in 1980.
Under the terms of the agreement, Manazil will establish a light-steel frame manufacturing plant in the industrial zone of Abu Dhabi using the Genesis solution, a turn-key solution which includes leading edge software, industrial equipment, hardware, processes and engineering services ("Genesis Solution"). The plant is scheduled to be operational by early 2008 and will address the market opportunities created by the construction boom in the UAE, especially in Dubai and Abu Dhabi.
Given Abu Dhabi's strategic location, this agreement will help Genesis emerge as a player in the building industry in the fast growing UAE market. Maged Mostafa, Vice President of Business Development for Genesis, sees this as a breakthrough for Genesis, as Manazil will be able to serve a large portion of the Gulf region from its new plant.
"The Genesis Solution allows for the custom design and manufacture of buildings six storeys or less. Its inherent flexibility will allow Manazil to offer builders in the UAE structural solutions that meet their architectural requirements, but in a much more efficient fashion," said Mostafa.
Manazil was attracted to the Genesis Solution as it provides a clear alternative to traditional methods and materials and offers an energy efficient, fire resistant, cost-effective and fast building solution. Manazil selected the Genesis Solution after carefully assessing other types of building materials and systems.
Ali Muhsin, Project Manager of Manazil stated, "We believe that working together with Genesis will be the best solution to achieve our goals and offer a new, smart, fully integrated turn-key approach and more simplified construction solution to the Middle East area." The first phase of production will include the manufacturing of 200,000 square meters of panels intended to build 500 modern villas.
According to Mohammad Khalifa Al Fahad Al Mehairi, Chairman of the Board of Manazil, the contract signed with Genesis is the first of its kind in the Arabian Gulf and Middle East region. Manazil will be the sole provider of Genesis building systems in the United Arab Emirates and Qatar.
With the introduction of the Genesis Solution into the Gulf Region, Manazil expects to revolutionize the local building industry and bring substantial benefits to the market, including a reduction of building costs and construction time. It will also increase the lifespan and overall quality of buildings compared with traditional types of building construction.

AVVW compared to EFSF

EFSF 54M market cap

eFoodSafety.com, Inc. Announces Carmen Electra and Maria Menounos to Commence National Television Sales of PurEffect(TM) Anti-Acne Product
Wednesday July 11, 9:45 am ET


SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News) is pleased to announce that through its joint-venture partner, CK41 Direct, Inc., celebrities Carmen Electra and Maria Menounos have signed multi-year contracts to promote the company's PurEffect(TM) anti-acne product via nationally broadcast direct sales infomercials. Production began July 6, 2007. Under the current production schedule, PurEffect(TM) infomercials will begin broadcasting in Fall 2007. The company expects that sales revenue should follow almost immediately.

AVVW's skincare products

http://help4skincare.com/avvaa_skincare_products.html

A steroid-free product specifically formulated to relieve the symptoms and reduce recurrences of psoriasis, seborrheic dermatitis and other skin irritations. Quickly reduces dryness, scaling and itching. This moisturizing spray promotes and enhances the "feel" of the skin's natural texture.


FDA Compliant. Doctor Recommended.

Product Qualities:

* Immediate ITCH RELIEF !
* 98% Natural Ingredients
* A unique balance of therapeutic minerals and oils
* Non-greasy, fast drying formula
* Quick Cooling Effect
* With reduced symptoms, the skin's natural healing properties appear to take over
* Enhances the "feel" of the skin's natural texture





Medicinal Ingredient:
Salicylic Acid 2% w/v.
Non Medicinal Ingredients:
Water, ethereal oils, moisturizing oils, calcium, silica, and magnesium.

Does Not Contain:
Cortisone, alcohol, fluorocarbon propellants, antibiotics, or other unnatural ingredients or additives.

Warning:
Allergic reactions to this product, although rare, have been reported in the past. Do not take this product is you have any known allergies to the following ingredients: melaleuca alternifolia (tea tree oil), salicylic acid, glycerine, silica or silicitic acid, calcium carbonate, magnesium carbonate, phenoxyethanol, sapo calinus, methyl cellulose, benzoic acid or dehydroacetic acid. If you are uncertain, consult with your physician.

AVVW's skin products WOW


http://help4skincare.com/avvaa_skincare_products.html

whats with AVVW today


State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of April 16, 2007, we had 250,194,198 shares of common stock outstanding, $0.001 par value.

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of April 16, 2007, we had 250,194,198 shares of common stock outstanding, $0.001 par value.

per latest 10QSB

AT THIS STAGE... NWBO IS NOT A DAYTRADE STOCK...
IT IS A LONG TERM HOLD

NWBO'S PIPELINE

http://www.nwbio.com/clinical_dcvax_pipeline.php


BRAIN, PROSTATE, LUNG, OVARIAN, LIVER, HEAD&NECK, PANCREAS

NWBO's prostate cancer vaccine compared to DNDN and CEGE

http://www.nwbio.com/clinical_dcvax_prostate.php

DCVax® - Prostate: Phase III


Development stage: DCVax®-Prostate is entering a Phase III clinical trial that was cleared to proceed by the Food and Drug Administration in January of 2005. Data from a Phase I/II clinical trial support the overall safety of DCVax®-Prostate, and suggest that DCVax®-Prostate may induce an immune response . Clinical data obtained in this trial also suggest delayed times to progression of disease, especially in patients with no metastatic disease at entry.

Trial design: The Phase III clinical trial is a randomized, multi-center, double blinded clinical trial that will enroll 612 patients in the United States.

Indication: Patients with hormone independent, non-metastatic prostate cancer will be eligible for participation in this clinical trial. Other eligibility criteria include requirements around absolute PSA levels as well as PSA doubling time.

Endpoints: The primary endpoint for the Phase III clinical trial is survival free of disease progression. The first secondary endpoint is survival free of the development of symptoms arising from progression of disease. Other endpoints include the induction of immune responses, and overall survival.

Product: DCVax®-Prostate is manufactured using a patient’s own dendritic cells, loaded with a recombinant form of Prostate Specific Membrane Antigen (rPSMA). The dendritic cells are generated from monocytes obtained through a single leukapheresis.

Immunization schedule: Immunization starts when eligible patients have met all entry criteria, including the specified absolute PSA level and PSA doubling time. Immunizations will be given at weeks 0, 2, 4, 8, and at months 3, 6, 9, 12, 18, 24 and 30.


Previous Phase I/II Clinical Trials

The Phase I/II study evaluated 32 patients with hormone independent prostate cancer, both non-metastatic and metastatic. Twelve patients entered the study with no radiological evidence of metastatic disease, and 20 had between one and three bone and/or lymph node metastases.

The natural history of prostate cancer indicates that patients with rising PSA values while on hormone treatment progress to metastatic disease on average in about 28-36 weeks, dependent upon several prognostic factors such a PSA velocity, time on anti-androgen therapy and nadir PSA while on anti-androgen therapy. In the non-metastatic group of patients (n=12), none had progressed at 28 weeks and only half had progressed at 59 weeks. Based on these Phase I/II data, the delay of progression to metastatic disease during long-term follow-up of this subset of patients appears correlated with stabilization of PSA levels. This is the patient population that the company will focus on in the Phase III clinical trial.
We also measured a highly specific PSMA antibody response following immunization with DCVax®-Prostate, and a highly specific and strong T cell response to PSMA in about 80% of the patients treated with DCVax®-Prostate. Northwest Biotherapeutics’ expectation based on these data is that administration of DCVax®-Prostate will enhance progression free survival relative to placebo, delay the development of symptomatic disease and increase overall survival.

NWBO - DNDN - CEGE

DNDN has market cap of 644M

CEGE has market cap of 245M

NWBO has market cap of 22M...

NWBO should be trading at $100 per share

imo

http://biz.yahoo.com/seekingalpha/070710/40618_id.html?.v=1

Dendreon Has Competition: Northwest BioTherapeutics Gains Cancer Vaccine Approval
Tuesday July 10, 10:32 am ET

H.S. Ayoub submits: While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (NasdaqGM: DNDN - News) and Cell Genesys (NasdaqGM: CEGE - News), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancer.
According to the company;

In clinical trials, both newly diagnosed and recurrent brain cancer patients treated with DCVax®-Brain had more than double the survival time of patients who did not receive DCVax®-Brain (to over 33 months and continuing -- median not yet reached -- for newly diagnosed patients). In addition, unlike chemotherapy, DCVax®-Brain does not cause any debilitating side effects.

The stock more than tripled on the news, gaining 250% to end trading at $7.33 a share. Volume surged more than 100 times the 3-month daily average! What's ironic however, is the fact that the company is cleared to manufacture the vaccine in the U.S. and commercialize it in Switzerland, which according to the company;

"...increasingly noted for medical tourism, and is easily accessible for many medical tourists."

So, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008.

The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms. According to the company;

DCVax® products are personalized treatments, made by combining a patient's own master immune cells (dendritic cells) with cancer biomarkers derived from or displayed by the patient's own tumor.

and;

DCVax® products will be cost-effective. The key to their cost-effectiveness is a proprietary batch manufacturing process pioneered by NWBT, through over 10 years of development, under which a single manufacturing run is used to produce at least 3 years of personalized treatments for a particular patient. The treatments are stored frozen in single-dose vials, ready for use on an off-the-shelf basis for that patient. Such storage is highly reliable and low cost. By doing only one manufacturing run, and thereafter having the product available off-the-shelf, NWBT is able to keep the costs of its personalized vaccines at a level that can enable product pricing in a range comparable to other cancer drugs.

So, not only is Northwest BioTherapeutics producing a personalized vaccine to the individual patient, but it's also storing a 3 year stock pile for that patient at low cost.

The next couple of years look to be very promising for Northwest BioTherapeutics, but investors must be wary. Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again!

NWBO THE NEXT DNDN

Dendreon Has Competition: Northwest BioTherapeutics Gains Cancer Vaccine Approval
Tuesday July 10, 10:32 am ET

H.S. Ayoub submits: While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (NasdaqGM: DNDN - News) and Cell Genesys (NasdaqGM: CEGE - News), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancer.
According to the company;

In clinical trials, both newly diagnosed and recurrent brain cancer patients treated with DCVax®-Brain had more than double the survival time of patients who did not receive DCVax®-Brain (to over 33 months and continuing -- median not yet reached -- for newly diagnosed patients). In addition, unlike chemotherapy, DCVax®-Brain does not cause any debilitating side effects.

The stock more than tripled on the news, gaining 250% to end trading at $7.33 a share. Volume surged more than 100 times the 3-month daily average! What's ironic however, is the fact that the company is cleared to manufacture the vaccine in the U.S. and commercialize it in Switzerland, which according to the company;

"...increasingly noted for medical tourism, and is easily accessible for many medical tourists."

So, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008.

The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms. According to the company;

DCVax® products are personalized treatments, made by combining a patient's own master immune cells (dendritic cells) with cancer biomarkers derived from or displayed by the patient's own tumor.

and;

DCVax® products will be cost-effective. The key to their cost-effectiveness is a proprietary batch manufacturing process pioneered by NWBT, through over 10 years of development, under which a single manufacturing run is used to produce at least 3 years of personalized treatments for a particular patient. The treatments are stored frozen in single-dose vials, ready for use on an off-the-shelf basis for that patient. Such storage is highly reliable and low cost. By doing only one manufacturing run, and thereafter having the product available off-the-shelf, NWBT is able to keep the costs of its personalized vaccines at a level that can enable product pricing in a range comparable to other cancer drugs.

So, not only is Northwest BioTherapeutics producing a personalized vaccine to the individual patient, but it's also storing a 3 year stock pile for that patient at low cost.

The next couple of years look to be very promising for Northwest BioTherapeutics, but investors must be wary. Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again!

NWBO

http://thestockmasters.com/article_NWBO_070907.asp

But Northwest Bio. has an amazing product, and until shares hit that 52-week high, I'll be buying. Now however is not to the time to buy shares, let it cool down a bit, hopefully Cramer won't mention it on his show because if he does, the stock will be over inflated and never be worth the risk. However, there are a few items that I don't like, try not filling an annual report since 2004. Not a good sign. It's tough to evaluate the true "health" of the company, we know they have a stellar drug on their hands, but can they make it worth investing in their company stock?

At this point my fellow Masters, I don't want to speculate if Northwest Biotherapeutics can turn water into wine and become a stock worth investing your money and returning to the NASDAQ. The reverse stock split and selling DCVax-Brain this year is a huge plus for getting Northwest Biotherapeutics on the right track, but it may not be enough.

However, using my full Jedi mind power for stock market speculation, I'm seeing Northwest Biotherapeutics (NWBO.OB) get to $10 by October. They have a drug like no other in the world, and I'm sure the sufferers of brain cancer are more excited then anyone making a few grand from the stock today. It's a huge win people, and perhaps worth the risk if the company can provide a stronger guidance.

CTTD

http://cleanenergynews.blogspot.com/search/label/Boeing

http://news.moneycentral.msn.com/ticker/article.aspx?Feed=PZ&Date=20070131&ID=6417334&Sy....

LONDON, Jan. 31, 2007 (PRIME NEWSWIRE) -- CO2 Tech (Pink Sheets:CTTD) President, Ms. Helga Schotten, today announced that CO2 Tech will exhibit its new solution for reducing gaseous emissions from airplanes at high altitudes for Boeing's review.

Further to correspondence and understandings between CO2 Tech and Boeing, CO2 Tech will exhibit product features and prototype of its new anti-global warming solution to Boeing as early as Q2/2007. "We intend to collaborate with Boeing in testing this product after completion of our prototype in Q2/2007, so that Boeing may be the first aircraft manufacturer to implement the new anti-global warming system and successfully reduce air pollution," states Helga Schotten, President of CO2.

http://cleanenergynews.blogspot.com/search/label/Boeing

pre-split,,, NWBO is trading at 48 cents

does the IPhone violate HPNN's patent

I LIKE IT WHEN THEY SAY,,, THE WORLD'S FIRST....

NWBO


TO THE MOON

NWBO

WATCH THIS STOCK JUMP

NO MORE SHARES AVAILABLE...

THIS IS BETTER THAN DNDN

LOWER FLOAT

MORE VACCINE THERAPIES / PIPELINES

NWBO

The DCVax(R) Technology platform is anticipated to be applicable to most cancers. NWBT is already at the Phase III, pivotal trial stage in prostate cancer, and has also received FDA clearance for clinical trials in five other cancers (including lung cancer, the leading cause of cancer deaths worldwide). Clinical trial data to date in hormone independent prostate cancer patients have shown striking results similar to the results in brain cancer

NWBO


Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer. It has two platform technologies, dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company's primary products include DCVax-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent nonmetastatic prostate cancer, which cleared Phase III clinical trial; DCVax-Brain, a personalized dendritic cell vaccine, which is in Phase II clinical trials, for the treatment of Glioblastoma multiforme; and DCVax-LB, a Phase II clinical trial product for the treatment of non-small cell lung cancer. It also develops DCVax-L, a Phase I clinical trial product for the treatment of nonsmall cell lung cancer; and DCVax-Direct, a Phase I clinical trial product for the treatment of head and neck cancer, nonsmall cell lung, and brain cancers. In addition, Northwest develops CXCR4 antibody, which is in preclinical stage for the treatment of breast cancer, glioblastoma, colon cancer, and melanoma. The company was founded in 1996 and is headquartered in Bothell, Washington

NWBO


Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer. It has two platform technologies, dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company's primary products include DCVax-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent nonmetastatic prostate cancer, which cleared Phase III clinical trial; DCVax-Brain, a personalized dendritic cell vaccine, which is in Phase II clinical trials, for the treatment of Glioblastoma multiforme; and DCVax-LB, a Phase II clinical trial product for the treatment of non-small cell lung cancer. It also develops DCVax-L, a Phase I clinical trial product for the treatment of nonsmall cell lung cancer; and DCVax-Direct, a Phase I clinical trial product for the treatment of head and neck cancer, nonsmall cell lung, and brain cancers. In addition, Northwest develops CXCR4 antibody, which is in preclinical stage for the treatment of breast cancer, glioblastoma, colon cancer, and melanoma. The company was founded in 1996 and is headquartered in Bothell, Washington

NWBO'S PIPELINE... ALL AT 25M MARKET CAP

http://www.nwbio.com/clinical_dcvax_pipeline.php

NWBO'S PIPELINE... ALL AT 25M MARKET CAP

http://www.nwbio.com/clinical_dcvax_pipeline.php

NWBO IN DOUBLE DIGITS TOMORROW

WHAT A POWERFUL STOCK

NWBO

ANOTHER DNDN TO SKYROCKET

less than 5M shares after the split

this stock will skyrocket

NWBT's DCVax® is a platform technology which is anticipated to be applicable to most cancers. DCVax® works by mobilizing the full spectrum of immune response, both innate and adaptive, rather than just single immune agents such as antibodies alone or T cells alone. As such, DCVax® mobilizes the patient's immune system to function in its normal, natural way. This leads to both improved efficacy and lack of problematic toxicities. Unlike conventional cancer drugs, DCVax® does not cause any debilitating side effects.

the TRANSFORMERS did it

the WI-FiTV - IPOD / IPHONE channels are working

IPhone connection....

maybe